Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.36 |
| ▸ | BTK | Q06187 | 1/20 | 0.33 |
| ▸ | CIT | O14578 | 1/20 | 0.33 |
| ▸ | PRKCI | P41743 | 3/20 | 0.33 |
| ▸ | AXL | P30530 | 2/20 | 0.33 |
| ▸ | PIP4K2C | Q8TBX8 | 1/20 | 0.32 |
| ▸ | JAK3 | P52333 | 1/20 | 0.31 |
| ▸ | CCNK | O75909 | 1/20 | 0.31 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.31 |
| ▸ | TTBK1 | Q5TCY1 | 1/20 | 0.31 |
| ▸ | TTBK2 | Q6IQ55 | 1/20 | 0.31 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.30 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.30 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.30 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8737516 | 0.85 | BTK (0.36) | TAAR1BTKPRKCIAXLJAK3 | |
| SCHEMBL8735125 | 0.84 | PRKCI (0.42) | BTKCITPRKCIAXLJAK3 | |
| SCHEMBL8737717 | 0.81 | PIK3C3 (0.40) | TAAR1PRKCIAXL | |
| SCHEMBL6127940 | 0.76 | AXL (0.42) | BTKCITPRKCIAXLJAK3 | |
| SCHEMBL21726013 | 0.75 | AXL (0.38) | BTKPRKCIAXLJAK3CCNK | |
| SCHEMBL8737468 | 0.74 | AXL (0.36) | TAAR1PRKCIAXL | |
| SCHEMBL18999654 | 0.74 | CCR8 (0.33) | TAAR1 | |
| SCHEMBL18819909 | 0.73 | BTK (0.33) | BTKCAPN1 | |
| SCHEMBL19131034 | 0.71 | CCR8 (0.52) | CITPRKCIAXL | |
| SCHEMBL27439407 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8809318-B2 | Gamma secretase modulators | MERCK SHARP & DOHME CORP. (US) | 2014-08-19 | — | — | US | disclosed |
| US-8759337-B2 | Gamma secretase modulators | MERCK SHARP & DOHME CORP. (US) | 2014-06-24 | — | — | US | disclosed |
| US-20120135980-A1 | GAMMA SECRETASE MODULATORS | SCHERING CORPORATION | 2012-05-31 | — | — | US | disclosed |
| US-20120129846-A1 | GAMMA SECRETASE MODULATORS | Merck, Sharp & Dohme, Corp. | 2012-05-24 | — | — | US | disclosed |
| US-20120129846-A1 | GAMMA SECRETASE MODULATORS | Merck, Sharp & Dohme, Corp. | 2012-05-24 | — | — | US | disclosed |
| US-20110306593-A1 | GAMMA SECRETASE MODULATORS | MERCK SHARP & DOHME LLC | 2011-12-15 | — | — | US | disclosed |
| US-20110294784-A1 | GAMMA SECRETASE MODULATORS | MERCK SHARP & DOHME LLC | 2011-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110294784-A1 | GAMMA SECRETASE MODULATORS | BACE1, BACE2, GSAP | TAAR1 4054/4885BTK 3584/4885CIT 3871/4885 |
| US-20120135980-A1 | GAMMA SECRETASE MODULATORS | BACE1, BACE2, GSAP | TAAR1 4054/4885BTK 3584/4885CIT 3871/4885 |
| US-20120129846-A1 | GAMMA SECRETASE MODULATORS | BACE1, BACE2, PSEN1 | TAAR1 4235/4885BTK 2726/4885CIT 4418/4885 |
| US-20110306593-A1 | GAMMA SECRETASE MODULATORS | BACE1, BACE2, PSEN1 | TAAR1 3995/4885BTK 2580/4885CIT 4479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.